Chimeric antigen receptor (CAR) -T cell therapy has emerged as a groundbreaking advancement in the treatment of severe autoimmune diseases (AIDs). Unlike traditional immunosuppressive therapies that broadly dampen the immune response, this innovative approach precisely targets the root causes of disease. Consequently, clinicians are witnessing a shift from chronic management toward a potential systemic immune reset. This transition offers new hope for patients suffering from refractory conditions across various medical specialties.

Mechanistic Insights: How CAR-T Cell Therapy Works

The core of this technology involves engineering a patient’s T cells to recognize specific signaling molecules on pathogenic cells. These modified cells then systematically eliminate the harmful lineages responsible for autoimmune pathologies. Furthermore, the therapy facilitates an “immune cleansing” phenomenon. In this process, the destruction of autoreactive B cells allows for the repopulation of healthy, non-pathogenic immune cells. Therefore, CAR-T cell therapy not only treats the symptoms but effectively resets the patient's entire immune landscape.

Recent studies highlight the efficacy of both autologous and allogeneic platforms. While autologous therapies use the patient's own cells, allogeneic “off-the-shelf” options may eventually reduce costs and treatment delays. Researchers have explored these platforms across dermatological, neurological, and gastrointestinal systems. For instance, patients with systemic lupus erythematosus and systemic sclerosis have shown remarkable drug-free remission. Moreover, the safety profile remains favorable, with most adverse events like cytokine release syndrome being manageable in clinical settings.

Future Landscape of CAR-T Cell Therapy

Addressing current challenges is essential for the broad clinical translation of this technology. Issues such as manufacturing complexity and potential long-term toxicities require ongoing investigation. Additionally, the development of next-generation platforms will likely enhance safety and accessibility. As clinical trials progress globally and within India, this therapy represents a revolutionary strategy for managing refractory AIDs that do not respond to conventional medicine.

Frequently Asked Questions

Is CAR-T cell therapy available in India?

While CAR-T cell therapy is approved for certain blood cancers in India, its use for autoimmune diseases currently remains restricted to clinical trial settings in premier institutes.

What are the common side effects in autoimmune patients?

Patients may experience cytokine release syndrome or neurotoxicity. However, current evidence suggests these events are typically less severe in autoimmune cases compared to oncology treatments.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always consult a qualified healthcare provider for the diagnosis and treatment of any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Yu B et al. From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseases. Ann Med. 2026 Dec undefined. doi: 10.1080/07853890.2026.2627057. PMID: 41657283.


2. Müller F, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up. N Engl J Med. 2024;390(8):687-700.


3. Kansal R, et al. Sustained B cell depletion and remission of systemic lupus erythematosus after CD19-targeted CAR T cell therapy. Sci Transl Med. 2019;11(482):eaav1648.